Hepatitis B
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity
- Details
- Category: HBV Prevention
- Published on Friday, 11 January 2013 00:00
- Written by NIH
Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.
AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 18 December 2012 00:00
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
Researchers Discover Structure of Hepatitis B Antigen that Interferes with Immune Response
- Details
- Category: HBV Basic Science
- Published on Tuesday, 08 January 2013 00:00
- Written by NIH
Researchers from the University of Oxford and the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases have determined the crystal structure of the hepatitis B "e" antigen (HBeAg), which plays a role in immune tolerance and chronic hepatitis B virus (HBV) infection, according to a study published in the January 8, 2013, issue of the journal Structure. These findings may aid the development of new therapies that improve immune response against the virus.
AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. 
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate
- Details
- Category: HBV Vaccines
- Published on Friday, 21 December 2012 00:00
- Written by Dynavax
A U.S. Food and Drug Administration (FDA) committee last month concurred that Dynavax's investigational hepatitis B virus (HBV) vaccine Heplisav was effective in preventing infection, but a majority thought there was not enough data to show whether the vaccine is safe.
FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 04 December 2012 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.
More Articles...
- AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
- Coverage of the 2012 AASLD Liver Meeting
Web Design and Development by